Skip to main content
SpringerLink
Log in

Non-Hodgkin Lymphoma

  • Chapter
Book cover Cancer in Adolescents and Young Adults

Part of the book series: Pediatric Oncology ((PEDIATRICO))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bleyer WA, O’Leary M, Barr R, Ries LAG (eds) (2006) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD; also available at www.seer.cancer.gov/publications

    Google Scholar 

  2. Birch JM, Alston RD, Quinn M, Kelsey AM (2003) Incidence of malignant disease by morphological type, in young persons aged 12–24 years in England, 1979–1997. Eur J Cancer 39:2622–2631

    PubMed  CAS  Google Scholar 

  3. Perkins SL, Raphael M, McCarthy K, et al (2003) Pediatric mature B-cell lymphoma: distribution of lymphoma subtype varies between national groups. Results from the FAB/LMB96 International Cooperative Group Study. Blood 102:1428 (abstract)

    Google Scholar 

  4. Jaffe E, Harris N, Stein H, Vardiman J (eds) (2000) World Health Organization Classifiction of Tumors. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Washington DC

    Google Scholar 

  5. Harris N, Jaffe E, Stein H, et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    PubMed  CAS  Google Scholar 

  6. Shipp MA, Ross KN, Tamayo P, et al (2002) Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. Nat Med 8:68–74

    PubMed  CAS  Google Scholar 

  7. Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 7:332–339

    PubMed  CAS  Google Scholar 

  8. Patte C, Sakiroglu C, Ansoborlo S, et al (2002) Urateoxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d’Oncologie Pédiatrique LMB89 protocol. Ann Oncol 13:789–795

    PubMed  CAS  Google Scholar 

  9. Pui CH, Mahmoud HH, Wiley JM, et al (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697–704

    PubMed  CAS  Google Scholar 

  10. Goldman SC, Holcenberg JS, Finklestein JZ, et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998–3003

    PubMed  CAS  Google Scholar 

  11. Coiffier B, Mounier N, Bologna S, et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21:4402–4406

    PubMed  CAS  Google Scholar 

  12. Patte C, Philip T, Rodary C, et al (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4:1219–1226

    PubMed  CAS  Google Scholar 

  13. Patte C, Philip T, Rodary C, et al (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132

    PubMed  CAS  Google Scholar 

  14. Patte C, Auperin A, Michon J, et al (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379

    PubMed  CAS  Google Scholar 

  15. Reiter A, Schrappe M, Parwaresch R, et al (1995) Non-Hodgkin lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage — a report of the Berlin-Frankfurt-Munster group. J Clin Oncol 13:359–372

    PubMed  CAS  Google Scholar 

  16. Reiter A, Schrappe M, Tiemann M, et al (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHLBFM 90. Blood 94:3294–3306

    PubMed  CAS  Google Scholar 

  17. Magrath I, Adde M, Shad A, et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934

    PubMed  CAS  Google Scholar 

  18. Atra A, Gerrard M, Hobson R, et al (1998) Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin lymphoma (B-NHL) — results of the UKCCSG 9003 protocol. Br J Cancer 77:2281–2285

    PubMed  CAS  Google Scholar 

  19. Atra A, Imeson JD, Hobson R, et al (2000) Improved outcome in children with advanced stage B-cell non-Hodgkin lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 82:1396–1402

    PubMed  CAS  Google Scholar 

  20. Spreafico F, Massimino M, Luksch R, et al (2002) Intensive, very short-term chemotherapy for advanced Burkitt lymphoma in children. J Clin Oncol 20:2783–2788

    PubMed  CAS  Google Scholar 

  21. Murphy SB, Hustu HO, Rivera G, Berard CW (1983) End results of treating children with localized non-Hodgkin lymphomas with a combined modality approach of lessened intensity. J Clin Oncol 1:326–330

    PubMed  CAS  Google Scholar 

  22. Link MP, Shuster JJ, Donaldson SS, et al (1997) Treatment of children and young adults with early-stage non-Hodgkin lymphoma. N Engl J Med 337:1259–1266

    PubMed  CAS  Google Scholar 

  23. Meadows AT, Sposto R, Jenkin RD, et al (1989) Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 7:92–99

    PubMed  CAS  Google Scholar 

  24. Gerrard M, Cairo MS, Patte C, et al (2003) Results of the FAB international study in children and adolescents (C+A) with localised B-NHL (large cell [LCL], Burkitt [BL] and Burkitt-like [BLL]). Proc ASCO 22:795 (abstract)

    Google Scholar 

  25. Reiter A, Schrappe M, Zimmermann M, et al (2003) Randomized trial of high dose methotrexate I.V. infusion over 24 hours versus 4 hours as part of combination chemotherapy for childhood and adolescent B-cell neoplasms. A report of the BFM Group. J Pediatr Hematol Oncol 25:S2 (abstract)

    Google Scholar 

  26. Patte C, Gerrard M, Auperin A, et al (2003) Early treatment intensity has a major prognostic impact in the “intermediate risk” childhood and adolescent B-cell lymphoma: results of the international FAB LMB 96 trial. Blood 102:491 (abstract)

    Google Scholar 

  27. Pusill-Wachtsmuth B, Zimmermann M, Seidemann K, et al (2003) Non-Hodgkin-lymphoma of adolescence: treatment results in the pediatric multicenter studies NHL-BFM. J Pediatr Hematol Oncol 25:S2 (abstract)

    Google Scholar 

  28. Todeschini G, Tecchio C, Degani D, et al (1997) Eightyone percent event-free survival in advanced Burkitt lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 8:77–81

    PubMed  Google Scholar 

  29. Corbacioglu S, Eber S, Gungor T, et al (2003) Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol Oncol 25:327–329

    PubMed  Google Scholar 

  30. de Vries MJ, Veerman AJ, Zwaan CM (2004) Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin lymphoma. Br J Haematol 125:414–415

    PubMed  Google Scholar 

  31. Cairo MS, Sposto R, Hoover-Regan M, et al (2003) Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol 72:53–63

    PubMed  Google Scholar 

  32. Laver JH, Mahmoud H, Pick TE, et al (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105–109

    PubMed  Google Scholar 

  33. Patte C, Auperin A, Bergeron C, et al (2002) Large Bcell lymphoma (LBCL) in children: similarities and differences with Burkitt (BL) in children and LBCL in adults. Experience of the SFOP LMB89 study. Ann Oncol 13:110 (abstract #379)

    Google Scholar 

  34. Laver JH, Weinstein HJ, Hutchison RE, et al (2001) Lineage-specific differences in outcome for advanced stage large cell lymphoma in children and adolescents: results of a randomized phase III Pediatric Oncology Group Trial. Blood 98:345a (abstract)

    Google Scholar 

  35. Alizadeh AA, Eisen MB, Davis RE, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

    PubMed  CAS  Google Scholar 

  36. Coiffier B, Lepage E, Briere J, et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    PubMed  CAS  Google Scholar 

  37. Pfreundschuh MG, Trumper L, Ma D, et al (2004) Randomized intergroup trial of first line treatment for patients <= 60 years with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab — early stopping after the first interim analysis. Proc ASCO 23:6500 (abstract)

    Google Scholar 

  38. Savage KJ, Monti S, Kutok JL, et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871–3879

    PubMed  CAS  Google Scholar 

  39. Patte C, Gerrard M, Auperin A, et al (2003) Results of the randomised international trial FAB LMB 96 for the “intermediate risk” childhood and adolescent B-cell lymphoma: reduced therapy is efficacious. Proc ASCO 22:796 (abstract)

    Google Scholar 

  40. Seidemann K, Tiemann M, Lauterbach I, et al (2003) Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 21:1782–1789

    PubMed  CAS  Google Scholar 

  41. Lones MA, Perkins SL, Sposto R, et al (2000) Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J Clin Oncol 18:3845–3853

    PubMed  CAS  Google Scholar 

  42. Stein H, Mason DY, Gerdes J, et al (1985) The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858

    PubMed  CAS  Google Scholar 

  43. Rimokh R, Magaud JP, Berger F, et al (1989) A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol 71:31–36

    PubMed  CAS  Google Scholar 

  44. Morris SW, Kirstein MN, Valentine MB, et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin lymphoma. Science 263:1281–1284

    PubMed  CAS  Google Scholar 

  45. Chott A, Kaserer K, Augustin I, et al (1990) Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol 14:439–448

    PubMed  CAS  Google Scholar 

  46. Delsol G, Al Saati T, Gatter KC, et al (1988) Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130:59–70

    PubMed  CAS  Google Scholar 

  47. Nakamura S, Takagi N, Kojima M, et al (1991) Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese. Cancer 68:118–129

    PubMed  CAS  Google Scholar 

  48. Greer JP, Kinney MC, Collins RD, et al (1991) Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539–547

    PubMed  CAS  Google Scholar 

  49. Shiota M, Nakamura S, Ichinohasama R, et al (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86:1954–1960

    PubMed  CAS  Google Scholar 

  50. Gascoyne RD, Aoun P, Wu D, et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921

    PubMed  CAS  Google Scholar 

  51. Falini B, Pileri S, Pizzolo G, et al (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1–14

    PubMed  CAS  Google Scholar 

  52. Stein H, Foss HD, Durkop H, et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681–3695

    PubMed  CAS  Google Scholar 

  53. Fraga M, Brousset P, Schlaifer D, et al (1995) Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103:82–89

    PubMed  CAS  Google Scholar 

  54. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al (1998) ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91:2076–2084

    PubMed  CAS  Google Scholar 

  55. Jaffe ES (2001) Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219–228

    PubMed  CAS  Google Scholar 

  56. Willemze R, Beljaards RC (1993) Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973–980

    PubMed  CAS  Google Scholar 

  57. Vergier B, Beylot-Barry M, Pulford K, et al (1998) Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 22:1192–1202

    PubMed  CAS  Google Scholar 

  58. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME (1996) The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 87:3437–3441

    PubMed  CAS  Google Scholar 

  59. Drexler HG, Gignac SM, von Wasielewski R, et al (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14:1533–1559

    PubMed  CAS  Google Scholar 

  60. Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:5623–5637

    PubMed  CAS  Google Scholar 

  61. Gascoyne RD, Adomat SA, Krajewski S, et al (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin lymphoma. Blood 90:244–251

    PubMed  CAS  Google Scholar 

  62. Murphy SB (1994) Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol 5:31–33

    PubMed  Google Scholar 

  63. Seidemann K, Tiemann M, Schrappe M, et al (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97:3699–3706

    PubMed  CAS  Google Scholar 

  64. Sandlund JT, Pui CH, Santana VM, et al (1994) Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin lymphoma. J Clin Oncol 12:895–898

    PubMed  CAS  Google Scholar 

  65. Williams DM, Hobson R, Imeson J, et al (2002) Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 117:812–820

    PubMed  CAS  Google Scholar 

  66. Massimino M, Spreafico F, Luksch R, Giardini R (2001) Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol 37:97–102

    PubMed  CAS  Google Scholar 

  67. Brugieres L, Deley MC, Pacquement H, et al (1998) CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591–3598

    PubMed  CAS  Google Scholar 

  68. Suzuki R, Kagami Y, Takeuchi K, et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000

    PubMed  CAS  Google Scholar 

  69. Sandlund JT, Pui CH, Roberts WM, et al (1994) Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 84:2467–2471

    PubMed  CAS  Google Scholar 

  70. Cairo MS, Krailo MD, Morse M, et al (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate („Orange“) in children with advanced non-lymphoblastic non-Hodgkin lymphoma. A Children’s Cancer Group report. Leukemia 16:594–60

    PubMed  CAS  Google Scholar 

  71. Reiter A, Schrappe M, Tiemann M, et al (1994) Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12:899–908

    PubMed  CAS  Google Scholar 

  72. Mora J, Filippa DA, Thaler HT, et al (2000) Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer 88:186–197

    PubMed  CAS  Google Scholar 

  73. Abromowitch M, Sposto R, Perkins SL, et al (2002) Preliminary results of CCG-5941: a pilot study in children and adolescents with anaplastic large cell lymphoma. Ann Oncol 13:erratum

    Google Scholar 

  74. Fanin R, Silvestri F, Geromin A, et al (1996) Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/− radiotherapy) and autologous bone marrow transplantation. Blood 87:1243–1248

    PubMed  CAS  Google Scholar 

  75. Sternberg C (1916) Leukosarkomatose and myelobastenleukaamie. Beitr Pathol 61:75

    Google Scholar 

  76. Barcos MGP, Lukes RJ (1975) Malignant lymphoma of the convoluted lymphocytes: a new entity of possible T-cell type. In: Sinks L, Godden J (eds) Conflicts in Childhood Cancer: An Evaluation of Current Management. Liss, New York, p 147

    Google Scholar 

  77. Amylon MD, Shuster J, Pullen J, et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335–342

    PubMed  CAS  Google Scholar 

  78. Tubergen DG, Krailo MD, Meadows AT, et al (1995) Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin lymphoma: a Childrens Cancer Group study. J Clin Oncol 13:1368–1376

    PubMed  CAS  Google Scholar 

  79. Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98:1283–1291

    PubMed  Google Scholar 

  80. Reiter A, Schrappe M, Ludwig WD, et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416–421

    PubMed  CAS  Google Scholar 

  81. Thomas DA, Kantarjian HM (2001) Lymphoblastic lymphoma. Hematol Oncol Clin North Am 15:51–95

    PubMed  CAS  Google Scholar 

  82. Colgan JP, Andersen J, Habermann TM, et al (1994) Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin lymphoma. Leuk Lymphoma 15:291–296

    PubMed  CAS  Google Scholar 

  83. Hoelzer D, Gokbuget N, Digel W, et al (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379–4385

    PubMed  CAS  Google Scholar 

  84. Cairo MS, Raetz E, Perkins SL (2003) Non-Hodgkin lymphoma in children. In: Kufe DW, Pollock RE, Weichselbaum RR, et al (eds) Cancer Medicine (6th edition). Decker, London, pp 2337–2348

    Google Scholar 

  85. Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin lymphoma in childhood. N Engl J Med 334:1238–1248

    PubMed  CAS  Google Scholar 

  86. Perkins SL (2000) Work-up and diagnosis of pediatric non-Hodgkin lymphomas. Pediatr Dev Pathol 3:374–390

    PubMed  CAS  Google Scholar 

  87. Pilozzi E, Muller-Hermelink HK, Falini B, et al (1999) Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267–270

    PubMed  CAS  Google Scholar 

  88. Hojo H, Sasaki Y, Nakamura N, Abe M (2001) Absence of somatic hypermutation of immunoglobulin heavy chain variable region genes in precursor B-lymphoblastic lymphoma: a study of four cases in childhood and adolescence. Am J Clin Pathol 116:673–682

    PubMed  CAS  Google Scholar 

  89. Link MP, Donaldson SS, Berard CW, et al (1990) Results of treatment of childhood localized non-Hodgkin lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 322:1169–1174

    PubMed  CAS  Google Scholar 

  90. Anderson J, Jenkin R, Wilson J, et al (1993) Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 11:1024–1032

    PubMed  CAS  Google Scholar 

  91. Wollner N, Burchenal JH, Lieberman PH, et al (1976) Non-Hodgkin lymphoma in children. A comparative study of two modalities of therapy. Cancer 37:123–134

    PubMed  CAS  Google Scholar 

  92. Anderson J, Wilson J, Jenkin D, et al (1983) Childhood non-Hodgkin lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308:559–565

    PubMed  CAS  Google Scholar 

  93. Asselin B, Shuster JJ, Amylon M, et al (2001) Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 20:1464 (abstract)

    Google Scholar 

  94. Millot F, Suciu S, Philippe N, et al (2001) Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increasedrisk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 19:1935–1942

    PubMed  CAS  Google Scholar 

  95. Weinstein HJ, Cassady JR, Levey R (1983) Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1:537–541

    PubMed  CAS  Google Scholar 

  96. Hvizdala EV, Berard C, Callihan T, et al (1988) Lymphoblastic lymphoma in children — a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. J Clin Oncol 6:26–33

    PubMed  CAS  Google Scholar 

  97. Eden OB, Hann I, Imeson J, et al (1992) Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children’s Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 82:310–316

    PubMed  CAS  Google Scholar 

  98. Abromowitch M, Sposto R, Prkins S, et al (2000) Outcome of Children’s Cancer Group (CCG) 5941: A pilot study for the treatment of newly diagnosed pediatric patients with disseminated lymphoblastic lymphoma. Proc Am Soc Clin Oncol 19:2295 (abstract)

    Google Scholar 

  99. Coleman CN, Picozzi VJ Jr, Cox RS, et al (1986) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637

    PubMed  CAS  Google Scholar 

  100. Morel P, Lepage E, Brice P, et al (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078–1085

    PubMed  CAS  Google Scholar 

  101. Zinzani PL, Bendandi M, Visani G, et al (1996) Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 23:577–582

    PubMed  CAS  Google Scholar 

  102. Bouabdallah R, Xerri L, Bardou VJ, et al (1998) Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: pa report on 62 patients from a single center. Ann Oncol 9:619–625

    PubMed  CAS  Google Scholar 

  103. Sweetenham JW, Santini G, Qian W, et al (2001) Highdose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927–2936

    PubMed  CAS  Google Scholar 

  104. Levine JE, Harris RE, Loberiza FR, Jr., et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482

    PubMed  CAS  Google Scholar 

  105. Falini B, Pileri S, Zinzani PL, et al (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93:2697–2706

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Institut Gustave Roussy, Villejuif, 94800, France

    Catherine Patte M.D.

  2. St. Charles Medical Center, Bend, 2500 NE Neff Road, OR, 97701, USA

    Archie Bleyer M.D.

  3. Department of Pediatrics Children’s Hospital of NewYork-Presbyterian, Columbia University, 180 Fort Washington, New York, NY, 10032, USA

    Mitchell S. Cairo M.D.

Authors
  1. Catherine Patte M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Archie Bleyer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitchell S. Cairo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St. Charles Medical Center, Bend, Oregon, USA

    W. Archie Bleyer

  2. McMaster University, Hamilton, Ontario, Canada

    Ronald D. Barr

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Patte, C., Bleyer, A., Cairo, M.S. (2007). Non-Hodgkin Lymphoma. In: Bleyer, W.A., Barr, R.D. (eds) Cancer in Adolescents and Young Adults. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68152-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68152-6_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40842-0

  • Online ISBN: 978-3-540-68152-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation